. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA. 2009 Dec 16;302(23):2565-72. PubMed.

Recommends

Please login to recommend the paper.

Comments

Make a Comment

To make a comment you must login or register.

Comments on Primary Papers and News

  1. In a paper in the Journal of Alzheimer's Disease, we demonstrate that the oxysterol 27-hydroxycholesterol reduces leptin levels and increases levels of both Aβ and phosphorylated tau in organotypic slices from adult rabbit hippocampus. Interestingly, we show that treatment with leptin reversed the 27-OHC-induced increase in Aβ and phosphorylated tau by decreasing the levels of BACE-1 and GSK-3β, respectively. Our results suggest that cholesterol metabolites induce AD-like pathology by altering leptin signaling.

    References:

    . Leptin is Involved in Accumulation of Amyloid-beta and Tau Phosphorylation Induced by 27-Hydroxycholesterol in Organotypic Slices from Adult Rabbit Hippocampus. J Alzheimers Dis. 2009 Dec 7; PubMed.

    View all comments by Othman Ghribi
  2. Comment by Mark A. Smith, Steven Greco, Jane M. Johnston, J. Wesson Ashford, George Perry, Gemma Casadesus, Nikolaos Tezapsidis

    Leptin—A Key Pathogenic Modulator in Alzheimer Disease
    The finding that high levels of leptin are associated with a reduced incidence of Alzheimer disease (Lieb et al., 2009) is consistent with data from our laboratories showing that: 1) leptin lowers amyloid-β protein in vitro and in vivo (Fewlass et al., 2004); 2) leptin-mediated reductions of amyloid-β in transgenic animals are associated with improved cognition (Greco et al., 2010); and 3) leptin reduces tau phosphorylation (Greco et al., 2008) through AMPK (Greco et al., 2009b) and GSK3β (Greco et al., 2009a). These findings led us (Fewlass et al., 2004; Tezapsidis et al., 2009) and others (Erol, 2008; Lieb et al., 2009) to suggest that leptin offers significant promise as a novel therapeutic strategy for Alzheimer disease (see Business Wire article).

    References:

    . An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J Alzheimers Dis. 2008 Apr;13(3):241-53. PubMed.

    . Obesity-related leptin regulates Alzheimer's Abeta. FASEB J. 2004 Dec;18(15):1870-8. PubMed.

    . Chronic Leptin Supplementation Ameliorates Pathology and Improves Cognitive Performance in a Transgenic Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2009 Dec 14; PubMed.

    . Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci Lett. 2009 May 22;455(3):191-4. PubMed.

    . Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun. 2009 Feb 27;380(1):98-104. PubMed.

    . Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun. 2008 Nov 21;376(3):536-41. PubMed.

    . Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA. 2009 Dec 16;302(23):2565-72. PubMed.

    . Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis. 2009;16(4):731-40. PubMed.

This paper appears in the following:

News

  1. Weight, Weight, Don’t Tell Me—Leptin Lowers AD Risk?